Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tretinoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 5/20 | 1.00 |
| ▸ | RARA known ✓ | P10276 | 4/20 | 1.00 |
| ▸ | RARB known ✓ | P10826 | 4/20 | 1.00 |
| ▸ | RARG known ✓ | P13631 | 4/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 2/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | RORC | P51449 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tretinoin SCHEMBL3146 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL9123793 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL8399912 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL7846921 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982760 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL38299 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982761 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Alitretinoin SCHEMBL5331051 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL18667 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL20603086 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483587-B1 | ANALYSIS DEVICE AND ANALYSIS METHOD | JVCKENWOOD CORP (JP) | 2023-11-29 | — | — | EP | claimed |
| EP-3089743-B1 | COMBINATION OF AN ARSENIC COMPOUND AND AT LEAST ONE RETINOID FOR TREATING ACUTE MYELOID LEUKEMIA | INST NAT SANTE RECH MED (FR) | 2018-07-11 | — | — | EP | claimed |
| EP-3089743-A1 | COMBINATION OF AN ARSENIC COMPOUND AND AT LEAST ONE RETINOID FOR TREATING ACUTE MYELOID LEUKEMIA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-11-09 | — | — | EP | claimed |
| US-20160317579-A1 | COMBINATION OF AN ARSENIC COMPOUND AND AT LEAST ONE RETINOID FOR TREATING ACUTE MYELOID LEUKEMIA | UNIVERSITÉ PARIS CITÉ (FR) | 2016-11-03 | — | — | US | claimed |
| WO-2015101618-A1 | COMBINATION OF AN ARSENIC COMPOUND AND AT LEAST ONE RETINOID FOR TREATING ACUTE MYELOID LEUKEMIA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-07-09 | — | — | WO | claimed |
| US-7964639-B2 | Reducing toxicity; esterification; side effect reduction; skin disorders; wrinkle resistance; anticancer agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-06-21 | — | — | US | claimed |
| US-7763599-B2 | Modified retinoid compounds and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-27 | — | — | US | claimed |
| US-7750043-B2 | Modified retinoid compounds and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-06 | — | — | US | claimed |
| US-20080194534-A1 | Modified Retinoid Compounds and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-08-14 | — | — | US | claimed |
| US-7126017-B2 | Method of reducing toxicity of retinoids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-10-24 | — | — | US | claimed |
| EP-1585724-A2 | METHOD OF REDUCING TOXICITY OF RETINOIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-10-19 | — | — | EP | claimed |
| EP-1585723-A2 | MODIFIED RETINOID COMPOUNDS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-10-19 | — | — | EP | claimed |
| US-20050085539-A1 | Method of reducing toxicity of retinoids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-04-21 | — | — | US | claimed |
| US-20040167215-A1 | Modified retinoid compounds and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-26 | — | — | US | claimed |
| WO-2004064743-A2 | MODIFIED RETINOID COMPOUNDS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004065358-A2 | METHOD OF REDUCING TOXICITY OF RETINOIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-08-05 | — | — | WO | claimed |
| CN-122087387-A | Fault diagnosis system of combine harvester header cross-domain adaptation residual error network | — | 2026-05-26 | — | — | CN | disclosed |
| US-12616673-B2 | Compounds for use in the treatment of leukemia | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-05 | — | — | US | disclosed |
| WO-2004064743-A2 | MODIFIED RETINOID COMPOUNDS AND THEIR USES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-08-05 | — | — | WO | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167215-A1 | Modified retinoid compounds and their uses | RARB, RARA, RARG | RXRA 5/4885RARA 2/4885RARB 1/4885 |
| US-12616673-B2 | Compounds for use in the treatment of leukemia | PSMB3, PSMG3, PSMA3 | RXRA 83/4885RARA 17/4885RARB 16/4885 |
| US-20160317579-A1 | COMBINATION OF AN ARSENIC COMPOUND AND AT LEAST ONE RETINOID FOR TREATING ACUTE MYELOID LEUKEMIA | NPM1, RARA, MCL1 | RXRA 5/4885RARA 2/4885RARB 4/4885 |
| US-20080194534-A1 | Modified Retinoid Compounds and Their Uses | RARB, RARA, RARG | RXRA 5/4885RARA 2/4885RARB 1/4885 |
| US-20050085539-A1 | Method of reducing toxicity of retinoids | RARB, RARA, RARG | RXRA 5/4885RARA 2/4885RARB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.